Impact of delay in surgery or time to surgery on kidney cancer outcomes

A recent study published in the Journal of Urology this month looked at the waiting times from diagnosis to surgery and the impact this had on outcomes for kidney cancer patients. The time from diagnosis of a kidney tumour to removal of the tumour during surgery can be very worrying for patients and clinicians due […]

read more

Neutrophil-lymphocyte ratio as a prognostic biomarker in high-risk locally advanced kidney cancer

An analysis of the data collected during the S-TRAC study, in which patients with high-risk, localised renal cell carcinoma (RCC) were treated with adjuvant sunitinib (after surgery), showed that sunitinib improved disease-free survival over placebo, but not overall survival. Researchers decided to look at biomarkers for disease-free survival in this study. In this study, a […]

read more

Activity of cabozantinib after immunotherapy in advance kidney cancer

A retrospective study published in the European Journal of Cancer this month looked at the activity of cabozantinib after immune checkpoint inhibitors in people with metastatic clear cell renal cell carcinoma (RCC). The overall response rate was 36%, with a median overall survival of 13 months. Cabozantinib appeared to be well tolerated and there were […]

read more

Inflammatory biomarkers to predict outcomes in kidney cancer

There still remains the need for a reliable biomarker to predict outcomes for advanced kidney cancer patients. Scientists have been working hard to try to identify biomarkers that can predict clinical outcomes and the course of the disease in people with metastatic renal cell carcinoma (RCC). A recent study published in Pathology Oncology Research this […]

read more

Surgical treatment of inferior vena cava tumour thrombi in kidney cancer

The formation of a cancerous blood clot, or thrombus, in one of the main veins that transport blood from the body to the heart, the inferior vena cava, can be a complication in patients with renal cell carcinoma (RCC), occurring in 5-15% of cases. A recent study investigated the surgical treatment of kidney cancer patients […]

read more

Potential biomarker for response to nivolumab for kidney cancer

Nivolumab was the first immunotherapy to be approved for the second-line treatment of metastatic renal cell carcinoma (RCC). Although some patients have long-lasting responses to nivolumab, others have limited benefit and the majority of patients will eventually experience disease progression. There has been a lot of research to identify a biomarker for response to nivolumab, […]

read more

Potential screening blood test for early kidney cancer

Researchers at the Dana-Farber Cancer Institute in Boston, USA have used a DNA-sequencing blood test to identify some of the earliest signs of kidney cancer, for which a reliable screening test is not yet available. The researchers analysed sequences of DNA and tagged certain pieces of genetic code with molecules that alter their function. In […]

read more

New targeted therapy shows potential for previously treated metastatic kidney cancer

A phase II study published in Frontiers in Oncology last month investigated the potential of a new targeted therapy called anlotinib for the treatment of people with metastatic renal cell carcinoma (RCC) that had already been treated with a VEGF tyrosine kinase inhibitor (TKI). Forty-two (42) patients were included in the study. The cancer progressed […]

read more

Ipilimumub plus nivolumab combination after prior treatment with immune checkpoint inhibitors

This retrospective study published in the Journal of Clinical Oncology looked at the response rates and progression-free survival of metastatic renal cell carcinoma (RCC) patients treated with a combination of ipilimumab plus nivolumab after previous treatment with an immune checkpoint inhibitor. Forty-five patients with metastatic RCC who had already been treated with an immune checkpoint […]

read more

Genetic profiling of renal medullary carcinoma paves the way for a potential treatment

Renal medullary carcinoma (RMC) is an aggressive cancer that mainly affects young people of African descent. It is resistant to all targeted agents used to treat other renal cell carcinomas (RCCs) and has limited therapeutic options. This study, published in the journal Cancer Cell analyses the genes of people with renal medullary carcinoma and finds […]

read more
Showing 1 to 10 of 628 results
  TOP